

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Benjamin Oshlack et al.	Confirmation No.:	8290
Serial No.:	10/562,494	Art Unit:	1617
Filed:	September 9, 2004		
For:	PHARMACEUTICAL COMBINATIONS OF HYDROCODONE AND NALTREXONE		
Examiner:	Deirdre Renee CLAYTOR		
Docket No.:	200.1163US		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

March 16, 2010


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Further to the Information Disclosure Statement filed on February 25, 2010, Applicants submit herewith a copy of the Japanese Office Action issued on November 10, 2009 in connection with corresponding Japanese Patent Application No. 2006-528039 and the English translation of the Office Action.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b), "[b]efore the mailing of a first Office action after the filing of a request for continued examination under § 1.114." See 37 C.F.R. §1.97(b). Accordingly, it is believed that no fee is due. If it is determined that any fees are due in connection with the filing of this Information Disclosure Statement, the Commissioner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 
Oleg Ioselovich
Reg. No. 56,963

DAVIDSON, DAVIDSON & KAPPEL, LLC
Patents, Trademarks and Copyrights
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940